Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences Corp. (Nasdaq: EXAS) reported fourth-quarter 2020 revenue of $466.3 million, with full-year revenue reaching $1.49 billion. Q4 screening revenue grew by 9% to $249.7 million, while COVID-19 testing contributed $99.1 million. However, the company faced a net loss of $436.8 million, or $(2.79) per share, compared to a net income of $78.0 million last year. The acquisition of Base Genomics resulted in a $412.6 million research and development charge. Cash reserves stood at $1.84 billion.

Exact Sciences Corp. (Nasdaq: EXAS) announced its acquisition of Ashion Analytics from The Translational Genomics Research Institute (TGen). Ashion, a CLIA-certified sequencing lab, will enhance Exact's precision oncology portfolio, particularly in minimal residual disease (MRD) testing. The acquisition includes a 10-year research collaboration with TGen and City of Hope to develop advanced MRD testing. This partnership aims to expedite bringing innovative genomic solutions to cancer treatment, leveraging Ashion's expertise and TARDIS technology.

Exact Sciences Corp. (Nasdaq: EXAS) is set to release its fourth quarter 2020 financial results on February 16, 2021, after U.S. market close. Management will host a webcast and conference call at 5 p.m. EST to discuss the financial results and business progress. The company is a leading provider of cancer screening and diagnostic tests, with an emphasis on improving patient care through products like Cologuard and Oncotype DX. For further details, visit their official website.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in several upcoming investor conferences in February 2021, inviting investors to join via webcast. Key events include:

• BTIG Virtual MedTech Conference on February 18, 2021 at 10:30 a.m. EST
• Citi Healthcare Services Conference on February 24, 2021 at 9:50 a.m. EST
• SVB Leerink Global Healthcare Conference on February 25, 2021 at 1:40 p.m. EST

Investors can access the webcasts on the company's investor relations webpage.

Exact Sciences Corp. (Nasdaq: EXAS) has acquired a worldwide exclusive license for TARDIS technology from TGen, enhancing its position in precision oncology. This innovative approach enables noninvasive detection of minimal residual disease, particularly for patients with small amounts of tumor DNA post-treatment. TARDIS technology demonstrated up to a 100-fold improvement in sensitivity for detecting circulating tumor DNA. This collaboration aims to improve cancer patient outcomes through advanced diagnostics, leveraging Exact Sciences' established expertise with products like Cologuard and Oncotype DX.

Exact Sciences Corp. (Nasdaq: EXAS) announced findings published in Cancer Prevention Research, highlighting the effectiveness of Cologuard in screening average-risk adults aged 45-49 for colorectal cancer. The study revealed a test specificity of 95.2% for participants without advanced precancerous lesions. The research supports Cologuard's role in mitigating risks and costs associated with unnecessary procedures. With colorectal cancer being the second leading cause of cancer death in the U.S., this data emphasizes the importance of early detection, especially as cases in younger adults have significantly increased.

Exact Sciences Corp. (Nasdaq: EXAS) anticipates reporting a 2020 fourth-quarter revenue of $464.5 million to $467.5 million. Expected Screening revenue is projected between $249 million and $250 million, marking a 9% increase year-over-year. The company anticipates Precision Oncology revenue of $117 million to $118 million and COVID-19 testing revenue between $98.5 million and $99.5 million. While these estimates are promising, they are preliminary and subject to change pending completion of the financial statements.

Exact Sciences Corp. (Nasdaq: EXAS) has finalized its acquisition of Thrive Earlier Detection Corp., a significant move towards establishing blood-based multi-cancer screening as a standard practice. CEO Kevin Conroy emphasized the strategic importance of this acquisition in revolutionizing cancer diagnostics and improving early detection and treatment options for patients. The company is committed to advancing its product pipeline, building on successes like Cologuard and Oncotype DX. This acquisition is aimed at addressing some of the most lethal cancers and enhancing patient care.

Exact Sciences Corp. (Nasdaq: EXAS) will participate in the J.P. Morgan Healthcare Conference on January 13, 2021, at 2:50 p.m. EST. Investors can join the discussion via webcast, accessible through the investor relations section of Exact Sciences' website.

This leading cancer diagnostics company aims to advance patient care and tackle deadly cancers through innovative solutions. For more details, visit exactsciences.com.